The Impact of Addition of Consolidation Chemotherapy to Standard Cisplatin-Based Chemoradiotherapy in Uterine Cervical Cancer: Matter of Distant Relapse

Table 2

Multivariate analysis for overall survival and progression free survival.

	OS		PFS
Characteristic	HR (95% CI)	p value	HR (95% CI)	p value
Consolidation CT
No	1	0.047	1	0.012
Yes	0.41 (0.16-0.99)		0.39 (0.18-0.81)
FIGO Stage
< IIB	1	0.049	-	-
> IIIA	1.97 (1.00-3.85)		-
Grade
1 and 2	1	0.090	1	0.077
3	1.78 (0.91-3.47)		1.71 (0.94-3.10)
Lymph node
Negative	-	-	1	0.006
Positive	-		2.48 (1.29-4.75)
Concurrent CT < 6 cycles
No	-	-	1	0.071
Yes	-		1.78 (0.95-3.33)

patients with complete data included in the multivariate analysis, 35 events.
² 135 patients with complete data included in the multivariate analysis, 46 events.
DMFS = distant metastasis free survival; LRFS = locorregional free survival; CT = chemotherapy.